Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

GT20029 is anticipated to start phase III trials in Q3 2026, with potential public availability around 2029-2030.

Users discussed the effectiveness of Everychem's solution, similar to PP405, with some reporting improved hair thickness and new growth. Concerns were raised about safety and the legitimacy of the product, with some users advising against purchasing research chemicals.

Some users report significant hair regrowth without microneedling, using treatments like finasteride, minoxidil, and dutasteride. Others believe microneedling enhances results, but opinions vary on its necessity.

Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.

The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.

The conversation humorously discusses hair loss treatments, mentioning electric stimulation and oral microneedling. It suggests skepticism towards traditional methods like pills and surgery.

New hair loss treatments like Breezula and a version of Minoxidil for hair regrowth are in advanced trials and may be available in a few years. Clascoterone and other treatments like oral and topical Minoxidil, Finasteride, and Dutasteride are also discussed, with some users experiencing side effects from Finasteride.

The user is currently using finasteride and minoxidil and is considering adding microneedling and either RU58841 or Pyrilutamide for potential hair regrowth. They previously used microneedling, RU58841, and oral minoxidil before their hair transplant.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

The conversation discusses hair loss treatments, specifically using finasteride, minoxidil, and microneedling. Recommendations for durable microneedling tools include the Derminator 2 and Dr. Pen.

CB-03-01, also known as Breezula, is being considered as an alternative to DHT blockers for hair loss. Users are discussing its effectiveness, potential regrowth, side effects like scalp irritation, and hormonal impacts.

A new plant-based serum is claimed to regrow hair in weeks, but users are skeptical about its effectiveness and the reliability of the study. Ingredients like Centella Asiatica and IGF-1 are mentioned, but many doubt the serum's superiority over existing treatments like Minoxidil and finasteride.

The conversation is about the effectiveness of Peptonix Peptide Infusion Hair Growth System for hair loss. The user is seeking feedback from others who have tried it, as there is limited data available.

Longitudinal partial follicular unit transplantation involves extracting part of the donor follicular unit, allowing the donor area to maintain hair production and potentially increasing transplant yield. The conversation questions if this method is practiced in clinics or remains theoretical, and whether it relates to hair cloning or multiplication.

The conversation discusses the availability and effectiveness of novel topical anti-androgens for hair loss, mentioning treatments like Breezula, GT20029, pyrilutamide, KX826, and RU58841. Users express skepticism about the effectiveness of these treatments and note that some are already available.

Minoxidil and finasteride are discussed for hair loss, with concerns about minoxidil's heart-related side effects. New treatments like PP405 are met with skepticism, often humorously noted as always being "five years away."

Key treatments for hair preservation include minoxidil, finasteride/dutasteride, and microneedling, with additional options like specific shampoos, oils, biotin, zinc, tretinoin, clascoterone, and low-level laser therapy. Maintaining a healthy lifestyle, reducing stress, and addressing nutrient deficiencies can also support hair health.

The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.

Treatments for hair loss, such as finasteride and minoxidil, as well as alternatives like stemoxydine and microneedling.

The user is exploring hair loss treatments in China, currently using finasteride and minoxidil, and is concerned about seborrheic dermatitis. Clinics are recommending selenium sulfide, doxycycline, and mesotherapy ampoules like PT88/PT66 or SP88/SP66, but the user is unsure about their effectiveness.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. Concerns about AI-generated content accuracy and misinformation are raised.

A user is seeking a European supplier for a 3-in-1 hair loss medication containing Minoxidil, Finasteride, and Biotin. Suggestions include using forwarding services and a UK-based provider, with discussions on potential import taxes.

The conversation discusses using minoxidil, finasteride, a dermastamp, and botanical oils like peppermint, rosemary, and pumpkin seed oil for hair growth. The user is considering using Alpha Infuse, which combines microneedling with plant oils, to enhance results.

Thymosin beta 4 injections for hair growth. Other treatments mentioned include Minoxidil, finasteride, and RU58841.

Dutasteride and high-dose Minoxidil are the primary treatments maintaining hair, with additional supplements and therapies like red light offering minimal extra benefit. The discussion criticizes promoting expensive hair care products when basic medications are doing most of the work.

The user has been microneedling at 0.25mm once a week for 4 weeks and noticed further hairline recession. They are concerned about the impact of vitamin deficiencies, like biotin, on hair growth.

The post and conversation are about skepticism towards a new hair loss treatment containing 2-deoxy-D-ribose, copper peptides, and exosomes, with concerns about the legitimacy of the product and its website. The treatment's effectiveness and authenticity are questioned due to lack of testing and transparency.

PP405 shows promise in regenerating hair by activating dormant follicles. Other treatments like VDPHL01 and Breezula are also advancing, providing new hope for hair loss solutions.

The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.

The conversation discusses the safety and trustworthiness of ordering RU58841 from Lyphar Biotech in China, with a focus on pricing and reliability. The user is seeking advice on whether to proceed with the purchase or consider alternative sources.